Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors

BACKGROUND: Cellular immunotherapies for cancer represent a means by which a patient’s immune system can be augmented with high numbers of tumor-specific T cells. Chimeric antigen receptor (CAR) therapy involves genetic engineering to ‘redirect’ peripheral T cells to tumor targets, showing remarkabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lontos, Konstantinos, Wang, Yiyang, Joshi, Supriya K, Frisch, Andrew T, Watson, McLane J, Kumar, Alok, Menk, Ashley V, Wang, Yupeng, Cumberland, Rachel, Lohmueller, Jason, Carrizosa, Esteban, Boyerinas, Benjamin, Delgoffe, Greg M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016249/
https://www.ncbi.nlm.nih.gov/pubmed/36914208
http://dx.doi.org/10.1136/jitc-2022-006522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016249/
https://www.ncbi.nlm.nih.gov/pubmed/36914208
http://dx.doi.org/10.1136/jitc-2022-006522

Ejemplares similares